Clinical Trials

Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)

Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)

RANDOMIZED, CONTROLLED, MULTI-CENTER STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF INTRAVITREAL AFLIBERCEPT COMPARED TO LASER PHOTOCOAGULATION IN PATIENTS WITH RETINOPATHY OF PREMATURITY (BUTTERFLEYE)

RANDOMIZED, CONTROLLED, MULTI-CENTER STUDY TO ASSESS

THE EFFICACY, SAFETY, AND TOLERABILITY OF INTRAVITREAL

AFLIBERCEPT COMPARED TO LASER PHOTOCOAGULATION IN

PATIENTS WITH RETINOPATHY OF PREMATURITY

Women’s Ischemia Trial to Reduce Events in Non-Obstructive CAD (WARRIOR)

Women’s Ischemia Trial to Reduce Events in Non-Obstructive CAD (WARRIOR)

Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Primary Objective:

To investigate effects of SAR440340 (anti-interleukin-33 [IL?33] monoclonal antibody [mAb]) compared with placebo, on the annualized rate of moderate-to-severe acute exacerbations of COPD (AECOPD) over up to 52 weeks of treatment.